Director/PDMR Shareholding
25 March 2021 15:00 GMT
Transactions by Persons Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announced that, on 23 and 24 March 2021, awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the AstraZeneca Deferred Bonus Plan (AZDBP) and AstraZeneca Performance Share Plans (AZPSP).
The AZDBP award was granted on 23 March 2018, following the deferral of a portion of each PDMR's annual bonus paid in respect of 2017 performance into Ordinary Shares, and vested on completion of the three-year holding period.
The AZPSP award was granted on 24 March 2016 and was subject to a three-year performance period. On the third anniversary of grant the award was placed in a two-year holding period. The award vested at the end of that holding period. Application of the performance measures specified at the time of grant resulted in 79% of the AZPSP award vesting and the remaining unvested part lapsing.
Following the reinvestment of dividends accrued during the performance and holding periods of the AZPSP award and during the deferral period of the AZDBP award, and the withholding of shares to satisfy certain tax obligations arising on vesting, the PDMRs' beneficial interests in Ordinary Shares changed as detailed in the table below:
PDMR | Ordinary Shares acquired under the AZDBP | Ordinary Shares acquired under the AZPSP |
Pascal Soriot | 13,241 | 110,966 |
Marc Dunoyer | 4,214 | 27,355 |
For tax purposes, the fair market value of an Ordinary Share at vest of the AZDBP award was 7344 pence, being the closing price on the last trading day preceding the vesting. The fair market value of an Ordinary Share at vest of the AZPSP award was 7215 pence, being the closing price on the last trading day preceding the vesting.
Further details are set out in the attached notifications, made in accordance with the requirements of the EU and UK Market Abuse Regulations.
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Pascal Soriot | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Executive Officer | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | AstraZeneca PLC | ||||
b) | LEI | PY6ZZQWO2IZFZC3IOL08 | ||||
4i | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292 | ||||
b) | Nature of the transaction | Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Deferred Bonus Plan, for nil consideration. | ||||
c) | Price(s) and volume(s) |
|
||||
d) | Aggregated information - Aggregated volume- Price | Not applicable - single transaction | ||||
e) | Date of the transaction | 23 March 2021 | ||||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Marc Dunoyer | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Financial Officer | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | AstraZeneca PLC | ||||
b) | LEI | PY6ZZQWO2IZFZC3IOL08 | ||||
4i | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292 | ||||
b) | Nature of the transaction | Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Deferred Bonus Plan, for nil consideration. | ||||
c) | Price(s) and volume(s) |
|
||||
d) | Aggregated information - Aggregated volume- Price | Not applicable - single transaction | ||||
e) | Date of the transaction | 23 March 2021 | ||||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Pascal Soriot | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Executive Officer | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | AstraZeneca PLC | ||||
b) | LEI | PY6ZZQWO2IZFZC3IOL08 | ||||
4i | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292 | ||||
b) | Nature of the transaction | Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Performance Share Plan, for nil consideration. | ||||
c) | Price(s) and volume(s) |
|
||||
d) | Aggregated information - Aggregated volume- Price | Not applicable - single transaction | ||||
e) | Date of the transaction | 24 March 2021 | ||||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Marc Dunoyer | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Financial Officer | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | AstraZeneca PLC | ||||
b) | LEI | PY6ZZQWO2IZFZC3IOL08 | ||||
4i | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292 | ||||
b) | Nature of the transaction | Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Performance Share Plan, for nil consideration. | ||||
c) | Price(s) and volume(s) |
|
||||
d) | Aggregated information - Aggregated volume- Price | Not applicable - single transaction | ||||
e) | Date of the transaction | 24 March 2021 | ||||
f) | Place of the transaction | Outside a trading venue |
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.